ZURICH (Reuters) – A late-stage clinical trial has shown therapy combining Roche’s immunotherapy Tecentriq with two of its other drugs helped people with a form of advanced melanoma, the Swiss drugmaker said on Friday.
The study met its primary aim of showing progression-free survival in patients with previously untreated BRAF V600 mutation-positive advanced melanoma, Roche said.
Adding Tecentriq, a monoclonal antibody, to Cotellic and Zelboraf helped reduce the risk of disease worsening or death compared to administering a placebo plus Cotellic and Zelboraf.”By combining a cancer immunotherapy with targeted therapies, we hope to offer a new approach that improves outcomes for people with advanced, BRAF-mutant melanoma,” said Levi Garraway, Roche’s chief medical officer and head of product development.
Roche has an extensive clinical trial development program for Tecentriq, with more than 50 studies for use in fighting lung, kidney, skin, breast, colorectal, prostate,…
Source news reuters.com, click here to read the full news.